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Since 1980う73patients with advanced testicular cancer have been treated with chemother斗pyand
43 patients received post-chemotherapy (salvage) surgery. The median age of al patients was 31 
years oldラ rangingfrom 17 to 63 years. The histology of the primary testicular tumor was pure 
seminoma in 23 patients and norトseminomain 50 patients. According to the japan Urological 
Association classification， 38 patients were classified as stage II and 35 patients as stage III. As first-
line chamotherapyラ 52patients were treated with PVB regimen (cisplatinラvinblastinぅbleomycin)う 16
patients with PEB (cisplatin， etoposideフ bleomycin) and 5 patients with V AB-6 (vinblastineラ
actinom ycin-Dラbleomycinラcisplatinラcyclophosphamide). Thirty (41 %) of the 73 patients achieved a 
complete response (CR) with chemotherapy alone and 63 (86%) achieved no evidence of disease 
(NED) with salvage treatment. As secondι.刷幽問心崎心.崎.
(いClSpμla剖tinラ etoposide)フ orVIP (etoposideう ifosfamideラ cisplatin)or VeIP (vinblastineラ ifosfamideラ
cisplatin). One of the 16 patients achieved CR and 1 (69%) patients achieved NED. 
As salvage surgeryラretroperitoneallymphnodedissection (RPLND) was performed in 22 patientsラ
RPLND with thoracotomy in 7 cases and thoracotomy alone in 4 cases. Necrosis was found in surgical 
specimens of 24 (56%) patients， mature teratoma in 6 (14%) and residual cancer in 13 (30%). 
Ninety-six percent and 100% of the patients with necrosis and mature teratoma survived with NEDう
respectivelyラbutonly 54% of the patients with residual carcinoma survived despite further treatment. 
Residual cancer was stil found in 8 of the 32 (25%) marker normalized cases. Residual cancer could 
not reliably be predicted or discriminated from necrosis or mature teratoma by the prognostic criteria. 
Thereforeラ salvagesurgery remains essential in the treatment of advanced testicular cancer. 
(Acta Urol. jpn. 45: 777-781う 1999)
























Patients characteristics with adv-
anced testicular cancer 
Age (years) 
median (range) 31 (17-63) 
Histology 
semlnoma 23 (32%) 
non-seロunoロla 50 (68%) 
Stage 
IIA 25 IIB 13 
IIIA 1 IIIB 24 IIIC 10 
Tumor burden 
non-bulky 28 (38 % ) 
bulky 45 (62%) 
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Fig. l. Treatment scheme and outcome of 
advanced testicular cancer. Marker 
十/ー positive/negativetumor marker 
at end point of chemotherapy. NED: 
no evidence of disease. 
は PVB療法52例， PEB療法16例， VAB-6療法 5例
である (Table1). 
進行性精巣腫楊の治療は，初期化学療法 (PVB，


















(Table 2). 初期化学療法のみの群の 5年生存率は
Table 2. Outcome of primary and salvage 
chemotherapy for advanced testicu-
lar cancer 
Chemotherapy No.of Outcome (%) 
response patlents Relapse Dead NED 
Primary 57 8 (14) 5 (9) 52 (91) 
CR 24 O O 24 
PR 33 8 5 28 
Salvage 16 3 (19) 5 (31) 1 (69) 
CR O O 
PR 12 3 2 10 
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10 
Salvage 16 
o o 3 4 
Observation period ( yea内)
Fig. 2. Survival rate of advanced testicular 
cancer according to primary or salvage 
chemotherapy. Seventy-three patients 
were divided into two groups of 57 
cases treated with first-li町 (primary)
chemotherapy only and 16 cases tr十

























Table 3. Histological findings of residual mas岨
ses according to pretreatment 
Histological五ndings(%) Out-
Salvage surgery Necro- Tera- come Cancer NED 
SIS toma 
Post-primary 21 (64) 3 ( 9) 9 (27) 28 (85) chem-. (33) 
Postmsalvloa} ge 3 (30) 3 ( 30) 4 (40) 8 (80) chem. ( 
Total 24 6 13 43 
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2 34 
Observation period ( years ) 
Fig. 3. Survival rate of advanced testicular 
cancer according to histological 




























Table 4. Histological findings of residual mas-
ses according to prognostic factors 
? ?
?










Meta. size Marker sta tus (%) 
>5cm >lOcm SI-3→Normalize 
Necrosis/ 24 16 五brosis
Mature 6 5 teratoma 
Cancer 13 1 
o 19 (79) 18 ( 95) 
o 6 (100) 6 (100) 
412 (92) 8 ( 67) 
TNM S categoryぅ SO:within normal limits after 
orchiectomy， SI: LDH<1.5N and HCG<5，000mIU/ 
ml and AFP< 1，000 ng/ml， S2: 1.5-lOXN or 5ラ000-



















や再燃症例に対して，われわれは， PE， VIP， VeIP 
療法を救済化学療法として行ってきた.これらの救済








1) 5 cm以上の後腹膜リンパ節転移， 2) 10カ所以上の
肺転移， 3) HCG 10，000 ng/ml以上， 4) AFP 1，000 
ng/ml以上， 5)肝臓，骨，中枢神経組織への転移
国際脹細胞腫蕩共同研究グループ(IGCCCG)
1 )ノンセミノーマ， 2)縦隔原発腫蕩， 3)精巣原発腫
傷 or後腹膜原発腫療の場合
腕以外の臓器転移 or麗蕩マーカー高値
(AFP> 10，000 ng/ml or HCG> 10，000 ng/mg or 
LDH>lOXN， Nは正常上限)
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Fig. 4. Survival rate of advanced testicular 
cancer accordi時 tothe jU A classifica-
tlOn. 
化学療法16例の治療成績は化学療法のみの CRが l
例 (6%)で， PRカq2例 (75%) で， NEDは1例

















Table 6. Outcome of salvage chemotherapy 
for refractory testicular cancer 
CR 
Author Regimen No.of with N(%ED ) patlents ch(e%m) o 
L(Io9e8h6r) er VIP 48 13 (27) 16 (33) 
E(1i9n9tl2o) rn VeIP 124 56 (45) 29 (23) 
E(1i9n9h2o) rn CE十ABMT 40 12 (30) 6 (15) 
S(i1e9g9e4r) t CEI+ABMT 68 21 (31) 19 (28) 
L(1a9m95p) e CE-トABMT 23 9 (39) 6 (26) 
h(f19o9tz6e) r CEC十ABMT 58 23 (40) 12 (21) 
自験例 VPCIP，T VeIP， 19 7 (37) 9 (47) 
Vう E:etoposide， Ve: vinb1astine， 1: ifosfamide， P 
CDDP， C: carboplatin， CEC: C十E十cyclophos-





















2. 救済化学療法の治療成績は， 16例中 CRはl
例， PRは12例， PDは3例，再燃は 3例， NEDは
1例 (69%) であった.
3. 残存組織が壊死に達した症例 (24例)の NED
は96%，成熟奇形腫(6例)では100%に対して，残
存癌(13例)では54%で予後不良であった.
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